Evidence map›Paper›PMID 29923081›Full record

SynthesisClinical rheumatology2018

Vasculitis associated with immune checkpoint inhibitors-a systematic review.

Anisha Daxini, Keri Cronin, Antoine G Sreih

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  14. Review
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Review
  20. Drug-associated abdominal aortitis and retroperitoneal fibrosis after treatment with nivolumab.Journal of vascular surgery cases and innovative techniques · 2025
    Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Anisha DaxiniDepartment of Internal Medicine, Mercy Nazareth Hospital, Philadelphia, PA, USA. anishadax@gmail.com.
Keri CroninDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
Antoine G SreihDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USNazareth Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent experimental and genetic studies have implicated the role of programmed cell death protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in the pathogenesis of medium and large vessel vasculitis. This study sought to evaluate the occurrence and nature of vasculitis associated with cancer treatment using immune checkpoint inhibition (anti-PD-1, anti-PDL-1, and anti-CTLA4). A systematic review of the medical literature was conducted by searching all available clinical data up to February 2018 in several databases and search engines including Cochrane Library, Embase, Google Scholar, Medline, Scopus, Web of Science, and Clinicaltrials.gov . Searches included the following FDA-approved anti-PD1 (nivolumab and pembrolizumab), anti-PDL1 (atezolizumab, avelumab, and durvalumab), and anti-CTLA4 (ipilimumab). The vasculitis cases were compiled and classified based on the 2012 revised Chapel Hill Consensus Conference nomenclature. The clinical feature of the vasculitis cases and their relationship to immune checkpoint inhibition was assessed. There were 53 cases of vasculitis of which 20 were confirmed. The main reported type of vasculitis was large vessel vasculitis and vasculitis of the central and peripheral nervous system. All cases resolved with either holding the immune checkpoint inhibitors and/or administering glucocorticoids. No death related to vasculitis was reported. Vasculitis, namely large vessel and vasculitis of the nervous system, is associated with immune checkpoint inhibition. Results of this study add to the growing evidence regarding the relationship between immune checkpoints and vasculitis and suggest that the pathway may be a therapeutic target.

Indexed as

Antineoplastic Agents, ImmunologicalB7-H1 AntigenCTLA-4 AntigenHumansImmunotherapyNeoplasmsProgrammed Cell Death 1 ReceptorVasculitisAntineoplastic Agents, ImmunologicalB7-H1 AntigenCTLA-4 AntigenProgrammed Cell Death 1 ReceptorCTLA-4Immune checkpoint inhibitorsPD-1PDL-1Vasculitis

Identifiers

PMID29923081
OpenAlexW2809144995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.